Analysts have ‘buy’ calls on Glenmark Pharmaceuticals Ltd., Hyundai Motor India Ltd., GE Vernova T&D India Ltd., Schneider Electric Infrastructure Ltd. and Prestige Estates Projects Ltd.
The stock calls came from Shrikant Chouhan, executive vice president and head equity research, Kotak Securities Ltd., Milan Vaishnav, CMT, MSTA, founder and technical analyst, Gemstone Equity Research and Sneha Seth, senior analyst, Angel One Ltd.
Glenmark Pharmaceuticals
Chouhan recommends buying the stock at Rs 1,551.4, with a target price of Rs 1,640 and a stop loss at Rs 1,500. Over the past 12 months, the stock has gained 87%, while its year-to-date performance stands at 79%. The relative strength index is at 45.
Of the 13 analysts tracking the stock, seven rate it a 'buy', four a 'hold' and two a 'sell', according to Bloomberg data. The consensus 12-month analysts' target price is Rs 1,745.8, indicating a potential upside of 13%.
Hyundai Motor India
Chouhan has suggested buying this stock at Rs 1,818.05 with a target price of Rs 1,930 and a stop loss of Rs 1,770. The stock has fallen by 0.9% since its listing in October.
As per Bloomberg data, 14 analysts cover the stock, with 11 assigning a 'buy' rating, and three a 'sell'. The 12-month analysts' consensus target is Rs 2,131, offering an expected upside of 17%.
GE Vernova T&D India
According to Vaishnav, the stock is a 'buy' at Rs 2,025, with a target price of Rs 2,150 and a stop loss at Rs 1,975. It has gained 345% in the last 12 months and 317% year-to-date. The stock’s relative strength index stands at 71.
Of the six analysts tracking the stock, five rate it 'buy' and one suggests 'hold', according to Bloomberg data. The consensus 12-month analysts' target price of Rs 2,165.2 per share implies a potential upside of 3%.
Schneider Electric
Vaishnav recommends purchasing the stock at Rs 860, with a target of Rs 920 and a stop loss at Rs 818. Over the past year, the stock has moved 106%, and in the year-to-date period, it has gained 111%. Its relative strength index is currently at 65.
Of the two analysts tracking the stock, as per Bloomberg, one recommends a 'buy' and one advocates 'sell'. The consensus target for the next 12 months is Rs 515, implying a potential loss of 40%.
Prestige Estates
Seth advises buying the stock at Rs 1,830.2 per share, targeting Rs 1,952 with a stop loss at Rs 1,757. The stock has shown a 62% change in the past 12 months and 57% year-to-date. The relative strength index is recorded at 66.
Bloomberg data indicates 20 analysts cover the stock, with 16 giving it a 'buy' and four a 'sell'. Analysts sets the target for the next 12 months at Rs 1,918.3, suggesting an upside of 2.5%.
RECOMMENDED FOR YOU
Market Experts' LIVE Stock Recommendations: Buy, Sell Or Hold Today?
Jul 04, 2025
Glenmark Pharma, Axis Bank, Bajaj Finance, Coforge, MCX and Aegis Vopak Are Buzzing On The Dealer Desk
Jul 01, 2025
Market Experts' LIVE Stock Recommendations: Hold Garden Reach, Buy Aurobindo Pharma
Jun 18, 2025
Market Experts' Stock Recommendations: Buy RVNL, Oracle Financial, Garden Reach
Jun 05, 2025
POPULAR